Background: In vitro activity of HMR 3270 a new peptide antifungal agent of the candin class was tested in comparison with fluconazole (FCZ), itraconazole (ITZ) and amphotericin B (AM.B). Material and methods: 248 yeasts strains isolated from clinical samples were tested according to a microtiter modification of the NCCLS M 27A method (difference in the final inoculum ~ 104/well). The NCCLS method was adapted to test 98 sporulating filamentous fungi. MIC (mg/L) was the lowest drug concentration that reduced growth by 80% (100% for AM.B). Results: The table indicates the MIC90 after 48h incubation for Candida spp and 72h for other species. C.alb S-FCZ n=30 C.alb R-FCZ n=33 C. gla n=30 C. kru n=29 C. kef n=10 C. lus n=10 C. pa n=31 C.tro n=32 C. neof n=30 Trichos n=13 HMR 0.19 0.5 1 4 1.3 4 4 2 8.8 8 FCZ 4 Â³64 Â³64 Â³64 Â³64 35.2 8 Â³64 8.8 8 ITZ Â³8 Â³8 Â³8 1.2 0.9 0.9 0.125 Â³8 0.5 1 AM.B 1 1 1 2 2 1.1 1 2 0.5 1 Against filamentous fungi: Aspergillus spp (n=50), Alternaria spp (n=6), Fusarium spp (n=12), Scedosporium apiospermum (n=20), S. inflatum (n=10), the ranges of MIC after 72h of incubation were 0.25 to Â³ 64 mg/L for HMR 3270, 0.015 to Â³ 8 mg/L for ITZ, 0.06 to Â³ 8 for AM.B and Â³ 64 mg/L for FCZ. Conclusion: HMR 3270 is a highly active compound against Candida. Promising preliminary results obtained in a model of systemic murine aspergillosis indicate that in vitro results against filamentous fungi may be test dependent. HMR 3270 deserves further in vitro and in vivo studies.
Full conference title:
- ICAAC 41st